{"id":"warfarine-low-molecular-heparin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bleeding"},{"rate":"5-10%","effect":"Nosebleeds"},{"rate":"5-10%","effect":"Bruising"},{"rate":"1-5%","effect":"Gastrointestinal bleeding"},{"rate":"<1%","effect":"Hemorrhagic stroke"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Warfarin acts as an anticoagulant by inhibiting the gamma-carboxylation of vitamin K-dependent clotting factors, including prothrombin and factors VII, IX, and X. This inhibition prevents the formation of blood clots and reduces the risk of thromboembolic events. The exact mechanism of warfarin's action is complex and involves multiple pathways, including the inhibition of vitamin K epoxide reductase and the subsequent depletion of vitamin K-dependent clotting factors.","oneSentence":"Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver, preventing blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:00.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation"},{"name":"Treatment and prevention of deep vein thrombosis and pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT00199602","phase":"PHASE3","title":"Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"1999-08","conditions":"Cancer","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"warfarine - low molecular heparin","genericName":"warfarine - low molecular heparin","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver, preventing blood clot formation. Used for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, Treatment and prevention of deep vein thrombosis and pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}